PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Securities Fraud Class Action

Case Background:
This is a federal securities fraud class action lawsuit on behalf of investors who purchased or otherwise acquired PROCEPT BioRobotics Corporation (“PROCEPT”) (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”).

PROCEPT is a commercial stage medical technology company focused primarily on the treatment of benign prostatic hyperplasia (“BPH”), also known as an enlarged prostate. One of the devices that PROCEPT manufactured and sold for the treatment of BPH was an Aquablation therapy system that utilized a single-use handpiece that was disposed of after the procedure.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) PROCEPT utilized a discount program to incentivize customers to place bulk orders in excess of demand; (2) the undisclosed discount program artificially inflated the company’s reported U.S. handpiece unit sales; (3) the consistent surplus of U.S. handpiece unit sales results in overstocking and exposed PROCEPT to material undisclosed risks of operational and financial harm; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Current Status of Case:
On September 22, 2026, Motions to Appoint Lead Plaintiff and Lead Counsel were filed. The Motions are in the process of being briefed. This action is ongoing.

If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at [email protected]. If you would like additional information about the suit, please click on the link “Submit Your Information” above and fill out the form as promptly as possible.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.